Corcept Therapeutics (CORT) Assets Average (2011 - 2026)
Corcept Therapeutics (CORT) posted Assets Average of $851.8 million for Q2 2026, up 3.15% sequentially from $825.8 million in Q1 2026, and up 3.36% YoY from $824.1 million in Q2 2025.
Corcept Therapeutics (CORT) Assets Average (2011 - 2026) Analysis & Trends
Corcept Therapeutics has reported Assets Average for 16 years, with the latest figure at $851.8 million in Q2 2026.
- Quarterly Assets Average rose 3.36% year-over-year to $851.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $851.8 million (up 3.36% YoY) and the FY2025 annual result came in at $838.6 million, up 14.71% from the prior year.
- Assets Average rose to $851.8 million in Q2 2026 per CORT's latest filing, from $825.8 million in the prior quarter.
- Over five years, Assets Average peaked at $851.8 million in Q2 2026 and troughed at $445.9 million in Q1 2022.
- A 5-year average of $678.6 million and a median of $662.0 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2023: Assets Average decreased 20.66% in 2022, then soared 34.69% in 2023.
- Over 5 years, Assets Average stood at $558.3 million in 2022, then increased by 8.85% to $607.8 million in 2023, then surged by 33.67% to $812.4 million in 2024, then grew by 2.18% to $830.1 million in 2025, then gained by 2.61% to $851.8 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $851.8 million, $825.8 million, and $830.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 851.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 851.79 Mn |
| Mar 31, 2026 | 825.77 Mn |
| Dec 31, 2025 | 830.13 Mn |
| Sep 30, 2025 | 812.66 Mn |
| Jun 30, 2025 | 824.09 Mn |
| Mar 31, 2025 | 843.50 Mn |
| Dec 31, 2024 | 812.41 Mn |
| Sep 30, 2024 | 749.41 Mn |
| Jun 30, 2024 | 685.25 Mn |
| Mar 31, 2024 | 638.73 Mn |
| Dec 31, 2023 | 607.77 Mn |
| Sep 30, 2023 | 559.32 Mn |
| Jun 30, 2023 | 571.24 Mn |
| Mar 31, 2023 | 600.64 Mn |
| Dec 31, 2022 | 558.34 Mn |
| Sep 30, 2022 | 514.81 Mn |
| Jun 30, 2022 | 482.24 Mn |
| Mar 31, 2022 | 445.94 Mn |
| Dec 31, 2021 | 504.58 Mn |
| Sep 30, 2021 | 576.94 Mn |